Sugi Predict

Sugi Predict / Compounds / SCHEMBL1438744

SCHEMBL1438744

SCHEMBL1438744

COCCN1CCC(C(N)=O)CC1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.66
▸ LTA4H P09960 2/20 0.50
▸ GAA P10253 2/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.45
▸ HRH3 Q9Y5N1 1/20 0.45
▸ HSD11B1 P28845 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ PARP1 P09874 1/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ PKM P14618 1/20 0.42
▸ CHRM1 P11229 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28743044 0.98 SMN1; SMN2 (0.64) SMN1; SMN2LTA4HGAANPSR1HRH3
SCHEMBL11972711 0.90 SMN1; SMN2 (0.54) SMN1; SMN2LTA4HGAANPSR1HRH3
SCHEMBL6176856 0.90 SMN1; SMN2 (0.62) SMN1; SMN2LTA4HGAANPSR1HRH3
SCHEMBL12437054 0.85 SMN1; SMN2 (0.47) SMN1; SMN2LTA4HHSD11B1PARP1
SCHEMBL791727 0.84 LTA4H (0.50) SMN1; SMN2LTA4HGAAHRH3HSD11B1
SCHEMBL30230392 0.83 SMN1; SMN2 (0.61) SMN1; SMN2LTA4HGAANPSR1HRH3
SCHEMBL9912397 0.82 TP53 (0.50) SMN1; SMN2LTA4HGAANPSR1HSD11B1
Hydrochloric Acid SCHEMBL4675628 0.82 LTA4H (0.49) SMN1; SMN2LTA4HGAAHRH3HSD11B1
SCHEMBL27820246 0.81 GBA1 (0.45) SMN1; SMN2LTA4HGAAHSD11B1PARP1
SCHEMBL13656328 0.81 SMN1; SMN2 (0.56) SMN1; SMN2LTA4HGAANPSR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011023812-A1 MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS NOVASAID AB (SE) 2011-03-03 — — WO claimed
EP-4395549-A1 COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL Oerth Bio LLC (US) 2024-07-10 — — EP disclosed
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 — — US disclosed
WO-2023034411-A1 COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL OERTH BIO LLC (US) 2023-03-09 — — WO disclosed
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2023-02-02 — — US disclosed
US-11214548-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2022-01-04 — — US disclosed
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2021-06-24 — — US disclosed
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2020-03-12 — — US disclosed
CN-110709085-A Compounds and methods for treating visceral pain 艾尼纳制药公司 2020-01-17 — — CN disclosed
US-20180354907-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2018-12-13 — — US disclosed
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 — — EP disclosed
US-9944606-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2018-04-17 — — US disclosed
US-8778950-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2014-07-15 — — US disclosed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 — — US disclosed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 — — US disclosed
WO-2011023812-A1 MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS NOVASAID AB (SE) 2011-03-03 — — WO disclosed
CN-1889951-A Substituted benzazoles and methods of their use as inhibitors of RAF kinase CHIRON CORP (US) 2007-01-03 — — CN disclosed
CN-1370144-A Aromatic sulfone hydroxamic acid metalloprotease inhibitor SEARLE & CO (US) 2002-09-18 — — CN disclosed
EP-1230219-A1 AROMATIC SULFONS HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. Searle & Co. (US) 2002-08-14 — — EP disclosed
WO-2000050396-A1 AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2000-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885LTA4H 1320/4885GAA 3665/4885
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 SMN1; SMN2 3930/4885LTA4H 478/4885GAA 718/4885
US-20180354907-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885LTA4H 1320/4885GAA 3665/4885
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885LTA4H 1320/4885GAA 3665/4885
US-11214548-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885LTA4H 1320/4885GAA 3665/4885
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 SMN1; SMN2 3930/4885LTA4H 478/4885GAA 718/4885
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885LTA4H 1320/4885GAA 3665/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885LTA4H 1320/4885GAA 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.